<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article article-type="case-report"><?DTDIdentifier.IdentifierValue thiemejournals20.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName thiemejournals20.xsd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName thiemexml2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol Surg Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol Surg Rep</journal-id><journal-id journal-id-type="doi">10.1055/s-00000182</journal-id><journal-title-group><journal-title>Journal of Neurological Surgery Reports</journal-title></journal-title-group><issn pub-type="ppub">2193-6358</issn><issn pub-type="epub">2193-6366</issn><publisher><publisher-name>Georg Thieme Verlag KG</publisher-name><publisher-loc>Stuttgart &#x000b7; New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5344796</article-id><article-id pub-id-type="doi">10.1055/s-0037-1598203</article-id><article-id pub-id-type="publisher-id">160034</article-id><article-categories><subj-group><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Remarkable Diagnostic Magnetic Resonance Imaging Findings in Sellar Xanthogranuloma: Report of Three First Cases in Latin America</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>C&#x000e9;spedes</surname><given-names>Mario Tapia</given-names></name><xref rid="AF160034-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Vargas</surname><given-names>Jaime Pinto</given-names></name><xref rid="AF160034-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ya&#x000f1;ez</surname><given-names>Fernando Andrade</given-names></name><xref rid="AF160034-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Le&#x000f3;n</surname><given-names>Loreto Spencer</given-names></name><xref rid="AF160034-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Arancibia</surname><given-names>Pablo &#x000c1;lvarez</given-names></name><xref rid="AF160034-5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Putz</surname><given-names>Thomas Schmidt</given-names></name><xref rid="AF160034-6" ref-type="aff">6</xref></contrib></contrib-group><aff id="AF160034-1"><label>1</label><institution>Department of Otorhinolaryngology &#x02013; Head and Neck Surgery, Regional Hospital of Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</institution></aff><aff id="AF160034-2"><label>2</label><institution>Department of Neurosurgery, Regional Hospital of Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</institution></aff><aff id="AF160034-3"><label>3</label><institution>Department of Radiology, Regional Hospital of Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</institution></aff><aff id="AF160034-4"><label>4</label><institution>Department of Pathology, Regional Hospital of Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</institution></aff><aff id="AF160034-5"><label>5</label><institution>Faculty of Medicine, University of Concepci&#x000f3;n, Concepci&#x000f3;n, Chile</institution></aff><aff id="AF160034-6"><label>6</label><institution>Department of Otorhinolaryngology - Head and Neck Surgery, University of Concepci&#x000f3;n, Chile</institution></aff><author-notes><corresp id="CO160034-1"><bold>Address for correspondence </bold>Thomas W. Schmidt Putz, MD <institution>Department of Otorhinolaryngology - Head and Neck Surgery, Specialty Department, University of Concepci&#x000f3;n</institution><addr-line>Chacabuco Avenue, No. 1401, Concepci&#x000f3;n</addr-line><country>Chile</country><email>Schmidtp@udec.cl</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2017</year></pub-date><volume>78</volume><issue>1</issue><fpage>e26</fpage><lpage>e33</lpage><history><date date-type="received"><day>17</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Thieme Medical Publishers</copyright-statement></permissions><abstract><p>The sellar xanthogranuloma is a rare lesion of the sellar&#x02013;parasellar region difficult to differentiate from other tumors such as craniopharyngiomas or Rathke's cleft cyst in the preoperative evaluation. As they are recently recognized as a separate entity and the few number of reports in the literature, its etiology is unknown and its impact remains uncertain. This article will describe the first three cases reported in Latin America, identified in one of them an imaging feature that may be helpful to elucidate an imaging growth pattern. Current evidence will be described regarding to the clinicopathological features, imaging diagnosis, and etiology origin theories.</p></abstract><kwd-group><title>Keywords</title><kwd>xanthogranuloma</kwd><kwd>craniopharyngioma</kwd><kwd>sellar region</kwd><kwd>MRI</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The World Health Organization (WHO) appointed xanthogranuloma of the sellar region as a specific type of brain tumor in 2000, differentiating it from adamantinomatous craniopharyngioma (CP). They are a rare entity, with two cases reported in the Western Hemisphere.<xref rid="JR160034-1" ref-type="bibr">1</xref>
<xref rid="JR160034-2" ref-type="bibr">2</xref> Histologically, xanthogranulomas correspond to a granulomatous reaction characterized by the presence of cholesterol crystals, foamy macrophages, giant cells, hemosiderin deposits, necrotic detritus, lymphocytic infiltrate, and fibrous proliferation.<xref rid="JR160034-3" ref-type="bibr">3</xref> Since the 37 cases were reported by Paulus et al,<xref rid="JR160034-3" ref-type="bibr">3</xref> 21 reports have been documented since 2000, without previous reports in Latin America.<xref rid="JR160034-2" ref-type="bibr">2</xref>
<xref rid="JR160034-4" ref-type="bibr">4</xref>
<xref rid="JR160034-5" ref-type="bibr">5</xref>
<xref rid="JR160034-6" ref-type="bibr">6</xref>
<xref rid="JR160034-7" ref-type="bibr">7</xref>
<xref rid="JR160034-8" ref-type="bibr">8</xref>
<xref rid="JR160034-9" ref-type="bibr">9</xref>
<xref rid="JR160034-10" ref-type="bibr">10</xref>
<xref rid="JR160034-11" ref-type="bibr">11</xref>
<xref rid="JR160034-12" ref-type="bibr">12</xref>
<xref rid="JR160034-13" ref-type="bibr">13</xref>
<xref rid="JR160034-14" ref-type="bibr">14</xref>
<xref rid="JR160034-15" ref-type="bibr">15</xref>
<xref rid="JR160034-16" ref-type="bibr">16</xref>
<xref rid="JR160034-17" ref-type="bibr">17</xref>
<xref rid="JR160034-18" ref-type="bibr">18</xref>
<xref rid="JR160034-19" ref-type="bibr">19</xref>
<xref rid="JR160034-20" ref-type="bibr">20</xref>
<xref rid="JR160034-21" ref-type="bibr">21</xref>
<xref rid="JR160034-22" ref-type="bibr">22</xref>
<xref rid="JR160034-23" ref-type="bibr">23</xref>
</p><p>The etiology of xanthogranulomas of the sellar region is controversial, and there are currently two hypotheses under greater discussion. The first states that xanthogranulomas originate from an inflammatory reaction, hemorrhage or rupture of a Rathke's cleft cyst (RCC). The second hypothesis postulates that xanthogranulomas arise from a secondary inflammatory progression of a CP.<xref rid="JR160034-19" ref-type="bibr">19</xref>
<xref rid="JR160034-21" ref-type="bibr">21</xref>
<xref rid="BR160034-24" ref-type="bibr">24</xref> Until now, there is no preoperative diagnostic method, imaging and immunohistochemical studies have not been sufficient by themselves to achieve accurate preoperative diagnosis.<xref rid="JR160034-1" ref-type="bibr">1</xref>
<xref rid="JR160034-9" ref-type="bibr">9</xref>
<xref rid="JR160034-20" ref-type="bibr">20</xref>
<xref rid="JR160034-21" ref-type="bibr">21</xref> We report three cases of sellar xanthogranuloma, highlighting an imaging finding in one of the cases that might be helpful to elucidate a characteristic pattern of these lesions.</p></sec><sec><title>Case 1</title><p>A 10-year-old patient, obese, with no other relevant medical history, presented with a 1-year history of recurrent episodes of headache associated with blurred vision, polyuria, and polydipsia. Magnetic resonance imaging (MRI) of the brain showed a cystic solid heterogeneous sellar mass with suprasellar extension, suggestive of CP or pituitary adenoma (<xref rid="FI160034-1" ref-type="fig">Figs. 1</xref> and <xref rid="FI160034-2" ref-type="fig">2</xref>). Goldmann perimetry showed a tubular visual field unrelated to the pituitary lesion.</p><fig id="FI160034-1"><label>Fig. 1</label><caption><p>
Case 1. (<bold>A</bold>) Coronal T2 and (<bold>B</bold>) coronal T1 postcontrast. Intrasuprasellar cystic hyperintense tumor with small solid hypointense peripheric nodule.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-1"/></fig><fig id="FI160034-2"><label>Fig. 2</label><caption><p>
Case 1. (<bold>A</bold>) Sagittal T1 precontrast and (<bold>B</bold>) sagittal T1 postcontrast. Sellar&#x02013;suprasellar hyperintense cystic tumor with a thin peripheric solid component (<bold>A</bold>). Solid peripheric component slightly enhanced, cystic component remains hyperintense (<bold>B</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-2"/></fig><p>An extended endoscopic transsphenoidal, transplanum, transselar, transtuberculum approach was performed. Macroscopically, the mass was described as similar to a CP with an old hematoma at its center. The patient had no postoperative complications. Histological examination revealed findings consistent with xanthogranuloma. At 38 months' follow-up after surgery, the patient had a significant improvement in visual disturbances, with no more headache episodes, polyuria, and polydipsia. The postoperative MRI confirmed the total tumor resection without recurrence or residual disease.</p></sec><sec><title>Case 2</title><p>A 35-year-old male patient, with a history of dyslipidemia, presented a 2-year history of recurrent headache, progressive visual loss, blurred vision, decreased libido and erectile dysfunction. The visual field test showed a superior temporal quadrantanopsia in the left eye and a temporal hemianopsia in the right eye. Endocrinological evaluation showed hypogonadism associated with secondary adrenal insufficiency. The MRI showed an expansive process of the sellar&#x02013;suprasellar region, partially cystic, slightly heterogeneous, hyperintense on T1-weighted and heterogeneous in T2-weighted image with calcifications, mass effect on the optic chiasm, and a retroclival dural tail with contrast enhancement (<xref rid="FI160034-3" ref-type="fig">Fig. 3</xref>).</p><fig id="FI160034-3"><label>Fig. 3</label><caption><p>
Case 2. (<bold>A</bold>) Sagittal T2, (<bold>B</bold>) sagittal T1 precontrast, and (<bold>C</bold>) sagittal T1 postcontrast. Sellar&#x02013;suprasellar solid cystic expansion process with predominance of cystic component hyperintense in T2, and a hypointense peripheric solid component (<bold>A</bold>). Cystic hyperintense in T1 (<bold>B</bold>). Solid peripheric component and retroclival dural tail slightly enhanced (<bold>C</bold>). Mass effect on optic chiasm.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-3"/></fig><p>An extended endoscopic transsphenoidal, transselar, transtuberculum, transplanum approach was made without complications. Histopathological examination showed the presence of cholesterol crystals, sclerosis and fibrosis of the connective tissue, cholesterol granulomas, lymphocytic infiltrate, hemosiderin deposits, and multinucleated giant cells without epithelial component, findings consistent with a xanthogranuloma (<xref rid="FI160034-4" ref-type="fig">Fig. 4</xref>). No complications developed in the postoperative period, except transient diabetes insipidus. At 8 months' follow-up after surgery, the patient had no more headache episodes; however, hypogonadism and visual field remain unimproved. Postoperative MRI showed a heterogeneous residual tumor appearance with a remnant of the retroclival dural tail before mentioned (<xref rid="FI160034-5" ref-type="fig">Fig. 5</xref>).</p><fig id="FI160034-4"><label>Fig. 4</label><caption><p>
(<bold>A</bold>) Hematoxylin&#x02013;eosin technique, fibrous tissue is observed with xanthogranulomatous chronic inflammation. (<bold>B</bold>) Crystals of cholesterol, inflammatory cells, and macrophages.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-4"/></fig><fig id="FI160034-5"><label>Fig. 5</label><caption><p>
Case 2. Postoperative (<bold>A</bold>) sagittal T1 precontrast, (<bold>B</bold>) sagittal T2, and (<bold>C</bold>) sagittal T1 postcontrast. Lesion suggestive of residual tumor, smaller than preoperative. Solid cystic sellar expansive process. The anterior thin solid peripheral component shows slightly enhancement postcontrast and remaining retroclival dural tail.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-5"/></fig></sec><sec><title>Case 3</title><p>A 31-year-old male patient, without morbid or surgical history, presented with a 2-year history of progressive decrease libido and erectile dysfunction associated with loss of muscle mass and progressive visual loss in the right eye. Endocrinological evaluation showed panhypopituitarism and brain MRI showed a sellar mass contacting the optic chiasm (<xref rid="FI160034-6" ref-type="fig">Fig. 6</xref>).</p><fig id="FI160034-6"><label>Fig. 6</label><caption><p>
Case 3. (<bold>A</bold>) Coronal T1 postcontrast and (<bold>B</bold>) sagittal T1 postcontrast. Intra- and suprasellar cystic tumor with small solid excentric extension, with predominance of T1 hyperintense cystic component, and a thin peripheral solid component which slightly enhanced postcontrast. Optic chiasm compression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-s-0037-1598203-i160034-6"/></fig><p>An extended endonasal endoscopic approach similar to previous cases was performed without complications. Histopathological findings were consistent with xanthogranuloma like the other cases. At 6 months' postoperative follow-up, the patient persisted with panhypopituitarism and visual deficit without improvement. Postoperative MRI showed complete tumor resection without residual lesion.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The xanthogranulomatous masses in the sellar&#x02013;parasellar region were considered as a variation of adamantinomatous CP.<xref rid="BR160034-25" ref-type="bibr">25</xref> Paulus et al<xref rid="JR160034-3" ref-type="bibr">3</xref> proposed this pathological pattern as a distinct clinicopathological entity and compared these lesions with CPs. They found several statistically significant differences highlighting the presentation at a younger age, intrasellar location, more severe endocrinological dysfunction, longer preoperative history, lower frequency of visual disturbances, and better surgical resectability with more favorable outcomes. Therefore, this entity was added to the WHO brain tumor classification in 2000, found mentioned in the third and fourth edition of the WHO classification of tumors of the central nervous system.<xref rid="BR160034-26" ref-type="bibr">26</xref>
<xref rid="BR160034-27" ref-type="bibr">27</xref>
</p><p>Most cases of xanthogranulomas of the sellar region have been reported in Asia with few reports in Western Hemisphere and none in Latin America. Therefore, the incidence of xanthogranulomas in the Western Hemisphere remains unknown. There is controversy regarding the origin of these rare lesions, and there are two main hypotheses under greater discussion. The first theory postulates that xanthogranulomas originate from an inflammatory reaction, hemorrhage, or rupture of a RCC. The second theory proposes their origin from a secondary inflammatory progression of a CP.<xref rid="JR160034-3" ref-type="bibr">3</xref>
<xref rid="JR160034-13" ref-type="bibr">13</xref>
<xref rid="JR160034-19" ref-type="bibr">19</xref>
<xref rid="JR160034-21" ref-type="bibr">21</xref>
<xref rid="BR160034-24" ref-type="bibr">24</xref> However, there is also reports related to systemic diseases such as sarcoidosis<xref rid="JR160034-7" ref-type="bibr">7</xref> and Erdheim&#x02013;Chester's disease.<xref rid="JR160034-5" ref-type="bibr">5</xref>
<xref rid="JR160034-16" ref-type="bibr">16</xref> The actual evidence is not yet conclusive regarding its etiology. The presence of squamous epithelium and calcifications reinforce the theory that relate xanthogranulomas to adamantinomatous CPs,<xref rid="JR160034-3" ref-type="bibr">3</xref> but the evidence gathered last year has been accumulating, favoring their origin related to RCC.<xref rid="JR160034-1" ref-type="bibr">1</xref>
<xref rid="JR160034-2" ref-type="bibr">2</xref>
</p><p>Clinically, they are characterized by the presence of cephalea, weight loss, anorexia, nausea, fatigue, visual disturbances, and endocrine disorders ranging from mild deficiencies of one or more hormone to panhypopituitarism. They have also been reported as a cause of diabetes insipidus of central origin (5&#x02013;10.19) and obstructive hydrocephalus.<xref rid="JR160034-15" ref-type="bibr">15</xref> All our cases were nonfunctioning tumors. In our series of cases, headache was the predominant symptom in one case, while in the other two cases were secondary to hypogonadism. Due to the rarity of this entity and considering its definitive diagnosis is by biopsy of the surgical specimen, the natural history of presentation of xanthogranuloma remains unknown, and there is no diagnostic method developed to achieve an accurate preoperative diagnosis to date. There are no typical radiological characteristics or patterns for xanthogranuloma.<xref rid="JR160034-9" ref-type="bibr">9</xref>
<xref rid="JR160034-20" ref-type="bibr">20</xref> They have variable levels of intensity secondary to unpredictable bleeding patterns and calcified lesions associated; therefore, it has not been possible to describe a typical imaging pattern presented consistently.</p><p>We have conducted a literature review of previously reported cases of xanthogranulomas of the sellar&#x02013;suprasellar region and elaborated a table focusing on the imaging characteristics with the intention of achieving an imaging pattern that contributes to the preoperative diagnosis (<xref rid="TB160034-1" ref-type="table">Table 1</xref>), without finding patterns or consistency in its MR signal characteristics. Recently, Madan Mohan et al<xref rid="JR160034-23" ref-type="bibr">23</xref> reported a case with residual tumor followed up with MR assessment revealing the development of new lesions that may illustrate a growth pattern, one of these lesions described was the development of a dural tail, also developed in our case 2, supporting it as an interesting feature that may elucidate a new imaging pattern that could be helpful in preoperative diagnosis.</p><table-wrap id="TB160034-1"><label>Table 1</label><caption><title>Sellar xanthogranuloma reported cases' features summary</title></caption><table rules="all"><colgroup align="left" span="10"><col align="left" width="40.5pt"/><col align="left" width="26.05pt"/><col align="left" width="57.4pt"/><col align="left" width="78.4pt"/><col align="left" width="67.85pt"/><col align="left" width="48.75pt"/><col align="left" width="48.75pt"/><col align="left" width="48.75pt"/><col align="left" width="52.35pt"/><col align="left" width="78.35pt"/></colgroup><thead><tr><th valign="bottom" align="left" rowspan="2">Author (year)</th><th valign="bottom" align="left" rowspan="2">Age/gender</th><th valign="bottom" align="left" rowspan="2">Clinical manifestation</th><th valign="bottom" align="left" rowspan="2">Clinical findings (Preop.)</th><th valign="bottom" align="left" rowspan="2">Location /size</th><th valign="bottom" align="left" colspan="3">MRI findings</th><th valign="bottom" align="left" rowspan="2">Tumor resection/approach</th><th valign="bottom" align="left" rowspan="2">Clinical findings (Postop.) and follow-up</th></tr><tr><th valign="bottom" align="left">T1</th><th valign="bottom" align="left">T2</th><th valign="bottom" align="left">Gd enhancement</th></tr></thead><tbody><tr><td valign="top" align="left">
<bold>Reithmeier et al (2002)</bold>
</td><td valign="top" align="left">51/M</td><td valign="top" align="left">Pallor, libido decrease</td><td valign="top" align="left">Panhypopituitarism, visual disturbances</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">NA</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">NA/transcranial</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left">
<bold>Yonezawa et al (2003)</bold>
</td><td valign="top" align="left">67/M</td><td valign="top" align="left">Fatigue, loss of appetite, weight loss</td><td valign="top" align="left">Pituitary dysfunction and hyponatremia</td><td valign="top" align="left">Intrasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Asymptomatic 3 mo</td></tr><tr><td valign="top" align="left">
<bold>Burt et al (2003)</bold>
</td><td valign="top" align="left">29/M</td><td valign="top" align="left">Cephalea, nausea</td><td valign="top" align="left">Panhypopituitarism and bitemporal hemianopsia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.8&#x02009;&#x000d7;&#x02009;1.5 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">NA</td><td valign="top" align="left">Periphery, heterogeneous</td><td valign="top" align="left">Subtotal/transsphenoidal</td><td valign="top" align="left">Favorable outcome 18 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">26/M</td><td valign="top" align="left">Decrease libido, fatigue, weight loss</td><td valign="top" align="left">Panhypopituitarism and hyperprolactinemia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">NA/transcranial</td><td valign="top" align="left">HRT, no recidiva at 8 mo</td></tr><tr><td valign="top" align="left">
<bold>Murao et al (2005)</bold>
</td><td valign="top" align="left">47/M</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left">
<bold>Jung et al (200</bold>6<bold>)</bold>
</td><td valign="top" align="left">57/F</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Bitemporal hemianopsia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.0&#x02009;&#x000d7;&#x02009;2.0&#x02009;&#x000d7;&#x02009;2.5 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">NA/transsphenoidal</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">5/M</td><td valign="top" align="left">Weakness, loss of appetite, cephalea</td><td valign="top" align="left">Diabetes insipidus, secondary adrenal insufficiency, hypothyroidism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.6 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">NA</td><td valign="top" align="left">Partial/transcranial</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left">
<bold>Tajima et al (2006)</bold>
</td><td valign="top" align="left">9/M</td><td valign="top" align="left">Polyuria, polydipsia</td><td valign="top" align="left">Pituitary dysfunction and hypothyroidism</td><td valign="top" align="left">Intrasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Diabetes insipidus, without recidiva 12 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">6/M</td><td valign="top" align="left">Polyuria, polydipsia</td><td valign="top" align="left">Diabetes insipidus</td><td valign="top" align="left">Intrasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Diabetes insipidus, HRT, without recidiva at 12 mo</td></tr><tr><td valign="top" align="left">
<bold>Liu et al (2008)</bold>
</td><td valign="top" align="left">32/M</td><td valign="top" align="left">Impairment of consciousness</td><td valign="top" align="left">Blurred vision</td><td valign="top" align="left">Suprasellar/3.4&#x02009;&#x000d7;&#x02009;3.8&#x02009;&#x000d7;&#x02009;4.2 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">NA/transcranial</td><td valign="top" align="left">Favorable outcome 6 mo</td></tr><tr><td valign="top" align="left">
<bold>Pav&#x000f3;n de Paz et al (2008)</bold>
</td><td valign="top" align="left">16/F</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Pituitary apoplexy and impairment of consciousness</td><td valign="top" align="left">Intrasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA/transsphenoidal</td><td valign="top" align="left">Without recidiva at 24 mo</td></tr><tr><td valign="top" align="left">
<bold>Moriya et al (2008)</bold>
</td><td valign="top" align="left">54/M</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left">
<bold>Sugata et al (2009)</bold>
</td><td valign="top" align="left">26/M</td><td valign="top" align="left">Polyuria, fatigue</td><td valign="top" align="left">Visual disturbances and pituitary dysfunction</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/3.0 cm</td><td valign="top" align="left">Isointense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Subtotal/transcranial</td><td valign="top" align="left">HRT, without recidiva at 12 mo</td></tr><tr><td valign="top" align="left">
<bold>Arai et al (2010)</bold>
</td><td valign="top" align="left">55/F</td><td valign="top" align="left">Cephalea and visual disturbances</td><td valign="top" align="left">Bitemporal hemianopsia, secondary adrenal insufficiency, and hypothyroidism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT, without recidiva at 18 mo</td></tr><tr><td valign="top" align="left">
<bold>Sulenti&#x00107; et al (2010)</bold>
</td><td valign="top" align="left">40/M</td><td valign="top" align="left">Cephalea, photophobia, and decreased libido</td><td valign="top" align="left">Panhypopituitarism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.5&#x02009;&#x000d7;&#x02009;2.0 cm</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT, sellar process at 6 mo</td></tr><tr><td valign="top" align="left">
<bold>Kamoshima et al (2011)</bold>
</td><td valign="top" align="left">8/F</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Diabetes insipidus and bitemporal hemianopsia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.1&#x02009;&#x000d7;&#x02009;1.1 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">11/M</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Diabetes insipidus and bitemporal hemianopsia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.0&#x02009;&#x000d7;&#x02009;1.2 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Isointense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">12/F</td><td valign="top" align="left">Growth delay</td><td valign="top" align="left">Panhypopituitarism and bitemporal hemianopsia</td><td valign="top" align="left">Suprasellar/3.0&#x02009;&#x000d7;&#x02009;1.7 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Total/transcranial</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">10/F</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Bitemporal hemianopsia</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.0&#x02009;&#x000d7;&#x02009;1.1 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">5/M</td><td valign="top" align="left">Polydipsia</td><td valign="top" align="left">Diabetes insipidus</td><td valign="top" align="left">Intrasellar/0.8&#x02009;&#x000d7;&#x02009;0.6 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">NA</td></tr><tr><td valign="top" align="left">
<bold>Agarwal et al (2012)</bold>
</td><td valign="top" align="left">41/M</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Panhypopituitarism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/NA</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Hypointense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Without recidiva at 6 mo</td></tr><tr><td valign="top" align="left">
<bold>Nishiuchi</bold>
<bold>et al. (2012)</bold>
</td><td valign="top" align="left">47/M</td><td valign="top" align="left">Cephalea, fatigue, and loss of appetite</td><td valign="top" align="left">Visual disturbances, hypothyroidism, and hypogonadism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.2&#x02009;&#x000d7;&#x02009;1.8&#x02009;&#x000d7;&#x02009;1.5 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT</td></tr><tr><td valign="top" align="left">
<bold>Tsai et al (2012)</bold>
</td><td valign="top" align="left">49/F</td><td valign="top" align="left">Cephalea and blurred vision</td><td valign="top" align="left">Visual disturbances, secondary adrenal insufficiency, and hypothyroidism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/4.0<bold>&#x02009;&#x000d7;&#x02009;</bold>4.0<bold>&#x02009;&#x000d7;&#x02009;</bold>5.0 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Subtotal/transcranial</td><td valign="top" align="left">Panhypopituitarism, visual disturbances unimproved, diabetes insipidus</td></tr><tr><td valign="top" align="left">
<bold>Amano et al (2013)</bold>
</td><td valign="top" align="left">20/M</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Diabetes insipidus and panhypopituitarism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.2 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Partial/transsphenoidal</td><td valign="top" align="left">HRT, diabetes insipidus, without recidiva at 84 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">64/M</td><td valign="top" align="left">Cephalea and diplopia</td><td valign="top" align="left">Hypogonadism and hypothyroidism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.8 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Partial/transsphenoidal</td><td valign="top" align="left">HRT, without recidiva at 63 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">12/M</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Visual disturbances, panhypopituitarism, and diabetes insipidus</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.0 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT, without recidiva at 45 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">40/F</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Panhypopituitarism and visual disturbances</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/3.2 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Subtotal/transsphenoidal</td><td valign="top" align="left">HRT, without recidiva at 31 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">59/F</td><td valign="top" align="left">Diplopia</td><td valign="top" align="left">Visual disturbances</td><td valign="top" align="left">Suprasellar/1.1 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Asymptomatic and without recurrence at 25 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">63/F</td><td valign="top" align="left">Cephalea and diplopia</td><td valign="top" align="left">Visual disturbances, hypogonadism, and hyperprolactinemia</td><td valign="top" align="left">Suprasellar/1.8 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT, without recurrence at 22 mo</td></tr><tr><td valign="top" align="left"/><td valign="top" align="left">68/M</td><td valign="top" align="left">Cephalea</td><td valign="top" align="left">Visual disturbances, panhypopituitarism, and diabetes insipidus</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/2.3 cm</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Subtotal/transsphenoidal</td><td valign="top" align="left">HRT, diabetes insipidus without recurrence at 12 mo</td></tr><tr><td valign="top" align="left">Case 1</td><td valign="top" align="left">10/M</td><td valign="top" align="left">Cephalea, polydipsia, polyuria, and blurred vision</td><td valign="top" align="left">Diabetes insipidus</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/0.7 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">No enhancement</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">Asymptomatic 35 mo follow-up</td></tr><tr><td valign="top" align="left">
<bold>Case 2</bold>
</td><td valign="top" align="left">35/M</td><td valign="top" align="left">Cephalea, decreased libido, erectile dysfunction, and visual disturbances</td><td valign="top" align="left">Left upper lateral quadrantanopsia, right hemianopsia, and hypogonadism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/3.5&#x02009;&#x000d7;&#x02009;2.5&#x02009;&#x000d7;&#x02009;2.6 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery and dural tail</td><td valign="top" align="left">Subtotal/transsphenoidal</td><td valign="top" align="left">HRT, hypogonadism, residual mass with retroclival dural tail at 6 mo follow-up</td></tr><tr><td valign="top" align="left">
<bold>Case 3</bold>
</td><td valign="top" align="left">31/M</td><td valign="top" align="left">Decreased libido, erectile dysfunction, muscle mass loss, and visual disturbances</td><td valign="top" align="left">Panhypopituitarism</td><td valign="top" align="left">Intrasellar&#x02013;suprasellar/1.5&#x02009;&#x000d7;&#x02009;1.5&#x02009;&#x000d7;&#x02009;1.6 cm</td><td valign="top" align="left">Hyperintense</td><td valign="top" align="left">Heterogeneous</td><td valign="top" align="left">Periphery</td><td valign="top" align="left">Total/transsphenoidal</td><td valign="top" align="left">HRT, without recurrence at 3 mo follow-up</td></tr></tbody></table><table-wrap-foot><fn id="FN160034-1"><p>Abbreviations: F, female; HRT, hormone replacement therapy; M, male; MRI, magnetic resonance imaging; NA, not available; Postop., postoperative; Preop., preoperative; T1, T1-weighted image; T2, T2-weighted image.</p></fn></table-wrap-foot></table-wrap><p>The increased risk of pituitary dysfunction compared with CP and RCC is probably due to bleeding, inflammation, or degeneration of a primary lesion. Regardless of tumor size, it appears that there is a better outcome when there is less intrasellar commitment and time between the onset of symptoms and the surgical resolution.<xref rid="JR160034-19" ref-type="bibr">19</xref> Surgical resection is the treatment of choice. The management has been almost universally treated by craniotomy or transsphenoidal microscopic surgery.<xref rid="JR160034-17" ref-type="bibr">17</xref>
<xref rid="JR160034-19" ref-type="bibr">19</xref>
<xref rid="JR160034-20" ref-type="bibr">20</xref> Our three cases were treated by endoscopic endonasal transsphenoidal approach achieving a satisfactory exposure with no morbidity related to the surgical procedure, being less invasive than craniotomy. Recurrences after complete resection are rare.<xref rid="JR160034-16" ref-type="bibr">16</xref> Radiotherapy has also been described as an effective treatment in a case of partial resection.<xref rid="JR160034-20" ref-type="bibr">20</xref>
</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Otolaryngologists and neurosurgeons must be cognizant of the existence of sellar xanthogranulomas as a differential diagnosis. We report the first three cases in Latin America, all of them operated by an endonasal endoscopic extended approach which allows a satisfactory exposure and gross tumor resection being a less invasive and effective approach to cure this pathology. The existence of a retroclival dural tail sign in a context of a sellar solid cystic lesions suspicious for a CP or RCC might be a specific feature that could raise the suspicion of a xanthogranuloma. Further studies with MRI assessment are needed to prove the reliability of this imaging characteristic.</p></sec></body><back><ack><title>Ethical Approval</title><p>This article does not contain any studies with animals performed by any of the authors. It corresponds to a retrospective study, according to the instructions for the authors for this type of study, formal consent is not required.</p></ack><fn-group><fn id="d30e157" fn-type="conflict"><p><bold>Conflict of Interest</bold> The authors declare no conflict of interest of any kind related to this article.&#x0000a;
&#x0000a;
<bold>Funding</bold>
&#x0000a;This work was supported financially by University of Concepci&#x000f3;n, Vice-Rector of Research and Development.</p></fn></fn-group><ref-list><title>References</title><ref id="JR160034-1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>B H</given-names></name><name><surname>Towfighi</surname><given-names>J</given-names></name><name><surname>Kapadia</surname><given-names>S B</given-names></name><name><surname>Lopes</surname><given-names>M B</given-names></name></person-group><article-title>Comparative immunohistochemical assessment of craniopharyngioma and related lesions</article-title><source>Endocr Pathol</source><year>2007</year><volume>18</volume><issue>01</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">17652797</pub-id></mixed-citation></ref><ref id="JR160034-2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmani</surname><given-names>R</given-names></name><name><surname>Sukumaran</surname><given-names>M</given-names></name><name><surname>Donaldson</surname><given-names>A M</given-names></name><name><surname>Akselrod</surname><given-names>O</given-names></name><name><surname>Lavi</surname><given-names>E</given-names></name><name><surname>Schwartz</surname><given-names>T H</given-names></name></person-group><article-title>Parasellar xanthogranulomas</article-title><source>J Neurosurg</source><year>2015</year><volume>122</volume><issue>04</issue><fpage>812</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">25614942</pub-id></mixed-citation></ref><ref id="JR160034-3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>W</given-names></name><name><surname>Honegger</surname><given-names>J</given-names></name><name><surname>Keyvani</surname><given-names>K</given-names></name><name><surname>Fahlbusch</surname><given-names>R</given-names></name></person-group><article-title>Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma</article-title><source>Acta Neuropathol</source><year>1999</year><volume>97</volume><issue>04</issue><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">10208277</pub-id></mixed-citation></ref><ref id="JR160034-4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>D E</given-names></name><name><surname>Ibrahim</surname><given-names>A E</given-names></name><name><surname>Ellison</surname><given-names>D W</given-names></name><name><surname>Armitage</surname><given-names>M</given-names></name><name><surname>Gawne-Cain</surname><given-names>M</given-names></name><name><surname>Lees</surname><given-names>P D</given-names></name></person-group><article-title>Inflammatory hypophysitis - the spectrum of disease</article-title><source>Acta Neurochir (Wien)</source><year>2002</year><volume>144</volume><issue>01</issue><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11807646</pub-id></mixed-citation></ref><ref id="JR160034-5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reithmeier</surname><given-names>T</given-names></name><name><surname>Trost</surname><given-names>H A</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name><name><surname>St&#x000f6;lzle</surname><given-names>A</given-names></name><name><surname>Feiden</surname><given-names>W</given-names></name><name><surname>Lumenta</surname><given-names>C B</given-names></name></person-group><article-title>Xanthogranuloma of the Erdheim-Chester type within the sellar region: case report</article-title><source>Clin Neuropathol</source><year>2002</year><volume>21</volume><issue>01</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">11846041</pub-id></mixed-citation></ref><ref id="JR160034-6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonezawa</surname><given-names>K</given-names></name><name><surname>Shirataki</surname><given-names>K</given-names></name><name><surname>Sakagami</surname><given-names>Y</given-names></name><name><surname>Kohmura</surname><given-names>E</given-names></name></person-group><article-title>Panhypopituitarism induced by cholesterol granuloma in the sellar region--case report</article-title><source>Neurol Med Chir (Tokyo)</source><year>2003</year><volume>43</volume><issue>05</issue><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">12790287</pub-id></mixed-citation></ref><ref id="JR160034-7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>M G</given-names></name><name><surname>Morey</surname><given-names>A L</given-names></name><name><surname>Turner</surname><given-names>J J</given-names></name><name><surname>Pell</surname><given-names>M</given-names></name><name><surname>Sheehy</surname><given-names>J P</given-names></name><name><surname>Ho</surname><given-names>K K</given-names></name></person-group><article-title>Xanthomatous pituitary lesions: a report of two cases and review of the literature</article-title><source>Pituitary</source><year>2003</year><volume>6</volume><issue>03</issue><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">14971740</pub-id></mixed-citation></ref><ref id="JR160034-8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murao</surname><given-names>K</given-names></name><name><surname>Imachi</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name></person-group><etal/><article-title>[Panhypopituitalism induced by xanthogranuloma of the sellar region]</article-title><source>Nippon Naika Gakkai Zasshi</source><year>2005</year><volume>94</volume><issue>12</issue><fpage>2597</fpage><lpage>2599</lpage><pub-id pub-id-type="pmid">16419600</pub-id></mixed-citation></ref><ref id="JR160034-9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C S</given-names></name><name><surname>Sch&#x000e4;nzer</surname><given-names>A</given-names></name><name><surname>Hattingen</surname><given-names>E</given-names></name><name><surname>Plate</surname><given-names>K H</given-names></name><name><surname>Seifert</surname><given-names>V</given-names></name></person-group><article-title>Xanthogranuloma of the sellar region</article-title><source>Acta Neurochir (Wien)</source><year>2006</year><volume>148</volume><issue>04</issue><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">16341628</pub-id></mixed-citation></ref><ref id="JR160034-10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>T</given-names></name><name><surname>Sawamura</surname><given-names>Y</given-names></name><name><surname>Ishizu</surname><given-names>K</given-names></name><name><surname>Tsubaki</surname><given-names>J</given-names></name></person-group><article-title>Two children with xanthogranuloma of the sellar region</article-title><source>Clin Pediatr Endocrinol</source><year>2006</year><volume>15</volume><issue>03</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">24790326</pub-id></mixed-citation></ref><ref id="JR160034-11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pav&#x000f3;n de Paz</surname><given-names>I</given-names></name><name><surname>Pe&#x000f1;alver Talavera</surname><given-names>D</given-names></name><name><surname>Olivar Rold&#x000e1;n</surname><given-names>J</given-names></name></person-group><etal/><article-title>Sellar xanthogranuloma</article-title><source>Endocrinol Nutr</source><year>2008</year><volume>55</volume><issue>02</issue><fpage>102</fpage><lpage>106</lpage>. Epub 2008 Oct 14. [Article in English]<pub-id pub-id-type="pmid">22964104</pub-id></mixed-citation></ref><ref id="JR160034-12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriya</surname><given-names>S</given-names></name><name><surname>Nimura</surname><given-names>T</given-names></name><name><surname>Utsunomiya</surname><given-names>A</given-names></name></person-group><etal/><article-title>Xanthogranuloma of the sellar region: a case report and review of literatures</article-title><source>Neurol Surg (Tokyo)</source><volume>18</volume><fpage>1024</fpage><lpage>1028</lpage></mixed-citation></ref><ref id="JR160034-13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugata</surname><given-names>S</given-names></name><name><surname>Hirano</surname><given-names>H</given-names></name><name><surname>Yatsushiro</surname><given-names>K</given-names></name><name><surname>Yunoue</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Arita</surname><given-names>K</given-names></name></person-group><article-title>Xanthogranuloma in the suprasellar region</article-title><source>Neurol Med Chir (Tokyo)</source><year>2009</year><volume>49</volume><issue>03</issue><fpage>124</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">19318739</pub-id></mixed-citation></ref><ref id="JR160034-14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>A</given-names></name><name><surname>Nishihara</surname><given-names>M</given-names></name><name><surname>Sasayama</surname><given-names>T</given-names></name></person-group><etal/><article-title>Xanthogranuloma of the sellar region--case report</article-title><source>Neurol Med Chir (Tokyo)</source><year>2010</year><volume>50</volume><issue>06</issue><fpage>488</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">20587976</pub-id></mixed-citation></ref><ref id="JR160034-15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z H</given-names></name><name><surname>Tzaan</surname><given-names>W C</given-names></name><name><surname>Wu</surname><given-names>Y Y</given-names></name><name><surname>Chen</surname><given-names>H C</given-names></name></person-group><article-title>Sellar xanthogranuloma manifesting as obstructive hydrocephalus</article-title><source>J Clin Neurosci</source><year>2008</year><volume>15</volume><issue>08</issue><fpage>929</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">18487047</pub-id></mixed-citation></ref><ref id="JR160034-16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulenti&#x00107;</surname><given-names>P</given-names></name><name><surname>Cupi&#x00107;</surname><given-names>H</given-names></name><name><surname>Cerina</surname><given-names>V</given-names></name><name><surname>Vrkljan</surname><given-names>M</given-names></name></person-group><article-title>Xanthogranuloma of the sellar region in a patient with sarcoidosis</article-title><source>Acta Clin Croat</source><year>2010</year><volume>49</volume><issue>01</issue><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">20635586</pub-id></mixed-citation></ref><ref id="JR160034-17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamoshima</surname><given-names>Y</given-names></name><name><surname>Sawamura</surname><given-names>Y</given-names></name><name><surname>Motegi</surname><given-names>H</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Houkin</surname><given-names>K</given-names></name></person-group><article-title>Xanthogranuloma of the sellar region of children: series of five cases and literature review</article-title><source>Neurol Med Chir (Tokyo)</source><year>2011</year><volume>51</volume><issue>10</issue><fpage>689</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">22027243</pub-id></mixed-citation></ref><ref id="JR160034-18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>H K</given-names></name></person-group><article-title>Xanthogranuloma of the sellar region. A case report</article-title><source>Neuroradiol J</source><year>2012</year><volume>25</volume><issue>02</issue><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">24028911</pub-id></mixed-citation></ref><ref id="JR160034-19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiuchi</surname><given-names>T</given-names></name><name><surname>Murao</surname><given-names>K</given-names></name><name><surname>Imachi</surname><given-names>H</given-names></name></person-group><etal/><article-title>Xanthogranuloma of the intrasellar region presenting in pituitary dysfunction: a case report</article-title><source>J Med Case Reports</source><year>2012</year><volume>6</volume><fpage>119</fpage></mixed-citation></ref><ref id="JR160034-20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>T S</given-names></name><name><surname>Tsui</surname><given-names>Y K</given-names></name><name><surname>Wu</surname><given-names>M WL</given-names></name></person-group><etal/><article-title>Xanthogrnauloma of sellar region: a case report with diagnostic imaging findings, treatment response and literature review</article-title><source>J Radiol Sci</source><year>2012</year><volume>37</volume><fpage>89</fpage><lpage>94</lpage></mixed-citation></ref><ref id="JR160034-21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>O</given-names></name><name><surname>Komori</surname><given-names>T</given-names></name></person-group><etal/><article-title>Clinicopathological features of sellar region xanthogranuloma: correlation with Rathke's cleft cyst</article-title><source>Brain Tumor Pathol</source><year>2013</year><volume>30</volume><issue>04</issue><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">23322180</pub-id></mixed-citation></ref><ref id="JR160034-22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyajima</surname><given-names>Y</given-names></name><name><surname>Oka</surname><given-names>H</given-names></name><name><surname>Utsuki</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name></person-group><article-title>Rathke's cleft cyst with xanthogranulomatous change--case report</article-title><source>Neurol Med Chir (Tokyo)</source><year>2011</year><volume>51</volume><issue>10</issue><fpage>740</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">22027255</pub-id></mixed-citation></ref><ref id="JR160034-23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan Mohan</surname><given-names>B</given-names></name><name><surname>Mohamed</surname><given-names>E</given-names></name><name><surname>Jain</surname><given-names>S K</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Jaiswal</surname><given-names>A K</given-names></name></person-group><article-title>Serial MR imaging in suprasellar xanthogranuloma: growth pattern and new lesions</article-title><source>J Neuroimaging</source><year>2015</year><volume>25</volume><issue>04</issue><fpage>677</fpage><lpage>679</lpage>. doi: 10.1111/jon.12170<pub-id pub-id-type="pmid">25291505</pub-id></mixed-citation></ref><ref id="BR160034-24"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>P C</given-names></name><name><surname>Scheithaeur</surname><given-names>B W</given-names></name><name><surname>Vogel</surname><given-names>F S</given-names></name></person-group><article-title>Surgical Pathology of the Nervous System and Its Coverings, 3rd ed</article-title><publisher-loc>New York</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><year>1991</year><fpage>537</fpage><lpage>545</lpage></mixed-citation></ref><ref id="BR160034-25"><label>25</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Al-Khalidi</surname><given-names>H</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name></person-group><article-title>Histopathological features of common pediatric brain tumors</article-title><publisher-loc>New York</publisher-loc><publisher-name>Demos Medical Publishing</publisher-name><year>2010</year><fpage>204</fpage><lpage>214</lpage></mixed-citation></ref><ref id="BR160034-26"><label>26</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rushing</surname><given-names>E J</given-names></name><name><surname>Giangaspero</surname><given-names>F</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name></person-group><etal/><article-title>Craniopharyngioma</article-title><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Press</publisher-name><year>2007</year><fpage>238</fpage><lpage>240</lpage></mixed-citation></ref><ref id="BR160034-27"><label>27</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kleihues</surname><given-names>P</given-names></name><name><surname>Cavenee</surname><given-names>W K</given-names></name></person-group>, eds. <article-title>Pathology and genetics of tumours of the nervous system. World Health Organization Classification of Tumours</article-title><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Press</publisher-name><year>2000</year></mixed-citation></ref></ref-list></back></article>